Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study
The effects of L-propionylcarnitine on walking capacity were assessed in a group of patients with peripheral vascular disease. in 12 patients. 300mg of L-propnionylcarnitine, given intravenously as a single bolus did not affect walking capacity, while 600mg increased both initial claudication distan...
Gespeichert in:
| Veröffentlicht in: | European heart journal 1992-02, Vol.13 (2), p.251-255 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 2 |
| container_start_page | 251 |
| container_title | European heart journal |
| container_volume | 13 |
| creator | BREVETTI, G. PERNA, S. SABBÀ, C. ROSSINI, A. SCOTTO DI UCCIO, V. BERARDI, E. GODI, L. |
| description | The effects of L-propionylcarnitine on walking capacity were assessed in a group of patients with peripheral vascular disease. in 12 patients. 300mg of L-propnionylcarnitine, given intravenously as a single bolus did not affect walking capacity, while 600mg increased both initial claudication distance from the placebo value of 179±114 to 245 ± 129 m (P |
| doi_str_mv | 10.1093/oxfordjournals.eurheartj.a060155 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72865309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72865309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-aefb88053efac61a680a747b98f5a53c6ee77707c36d77d4d3e10a128bdac24b3</originalsourceid><addsrcrecordid>eNpVkcGO0zAQhiMEWkrhEZB8QIhDU-w4thNOoBVQ0EocAGnFxZo4E-pu6mRtp7t9Lx4Ql1ZdcRrZ_-9vZvxn2RtGl4zW_O1w3w2-3QyTd9CHJU5-jeDjZglUUibEo2zGRFHktSzF42xGWS1yKavrp9mzEDaU0koyeZFdJKuQRTnL_nyfRvR28DbuydCRq3z0w2gHt-8NeGejdUh2Id0_HK0jdptsO-t-kzvobw7VwAjmAEnqCNGii4Hc2bgmB_64Rg892UEwUw-etDYgBHxHwBEwU8RFehc97NANU1iQdpiaHvOmt65dEOOHEPJhh56EOLX759mTLq2PL051nv389PHH5Sq_-vb5y-WHNCuvecwBu6aqqODYgZEMZEVBlaqpq06A4EYiKqWoMly2SrVly5FRYEXVtGCKsuHz7PWRm5a9nTBEvbXBYN-DwzSmVkUlBU-5zLP3R-O_ST12evR2C36vGdWH4PT_welzcPoUXEK8PPWami22D4BjUkl_ddLTH0LfeXDGhrNNMCWZOmDyo82GiPdnGfyNlooroVfXv3TJi6-S1oVe8b8M97_p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72865309</pqid></control><display><type>article</type><title>Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><creator>BREVETTI, G. ; PERNA, S. ; SABBÀ, C. ; ROSSINI, A. ; SCOTTO DI UCCIO, V. ; BERARDI, E. ; GODI, L.</creator><creatorcontrib>BREVETTI, G. ; PERNA, S. ; SABBÀ, C. ; ROSSINI, A. ; SCOTTO DI UCCIO, V. ; BERARDI, E. ; GODI, L.</creatorcontrib><description>The effects of L-propionylcarnitine on walking capacity were assessed in a group of patients with peripheral vascular disease. in 12 patients. 300mg of L-propnionylcarnitine, given intravenously as a single bolus did not affect walking capacity, while 600mg increased both initial claudication distance from the placebo value of 179±114 to 245 ± 129 m (P<0.05), and maximal walking distance from 245±124 to 349±155m (P<0.05). Once the efficacious dose of L-propionylcarnitine was assessed, its effect was compared to that of an equimolar dose of L-carnitine (500 mg i.v.) according to a double-blind, double-dummy, cross-over design. In 14 patients, both treatments improved walking capacity; however, the analysis of variance showed that the increase in maximal walking distance with L-propionylcarnitine was greater than that with L-carnitine (P < 0.05). Finally, in seven additional patients, the effects of L-propionylcarnitine and L-carnitine on the haemodynamics of the affected limb were assessed by an ultrasonic duplex system. Results indicated that both drugs did not affect the blood velocity and the blood flow rate in the ischaemic leg, thus suggesting that the beneficial effect on walking capacity was dependent on a metabolic effect. In conclusion, L-propionylcarnitine improves walking capacity in patients with peripheral vascular disease, probably acting through a metabolic mechanism. On a molar basis, this beneficial effect is greater than that observed with L-carnitine and, thus, the findings of the present study may have clinical relevance in terms of treatment cost and patient compliance.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/oxfordjournals.eurheartj.a060155</identifier><identifier>PMID: 1555624</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Arterial Occlusive Diseases - drug therapy ; Biological and medical sciences ; Cardiovascular system ; Carnitine - administration & dosage ; Carnitine - analogs & derivatives ; Dose-Response Relationship, Drug ; Double-Blind Method ; Exercise Test - drug effects ; Hemodynamics - drug effects ; Humans ; Infusions, Intravenous ; Intermittent Claudication - drug therapy ; Ischemia - drug therapy ; L-carnitine ; L-propionylcarnitine ; Leg - blood supply ; Male ; Medical sciences ; Middle Aged ; peripheral vascular disease ; Pharmacology. Drug treatments ; Vasodilator agents. Cerebral vasodilators ; walking capacity</subject><ispartof>European heart journal, 1992-02, Vol.13 (2), p.251-255</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-aefb88053efac61a680a747b98f5a53c6ee77707c36d77d4d3e10a128bdac24b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5176175$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1555624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BREVETTI, G.</creatorcontrib><creatorcontrib>PERNA, S.</creatorcontrib><creatorcontrib>SABBÀ, C.</creatorcontrib><creatorcontrib>ROSSINI, A.</creatorcontrib><creatorcontrib>SCOTTO DI UCCIO, V.</creatorcontrib><creatorcontrib>BERARDI, E.</creatorcontrib><creatorcontrib>GODI, L.</creatorcontrib><title>Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>The effects of L-propionylcarnitine on walking capacity were assessed in a group of patients with peripheral vascular disease. in 12 patients. 300mg of L-propnionylcarnitine, given intravenously as a single bolus did not affect walking capacity, while 600mg increased both initial claudication distance from the placebo value of 179±114 to 245 ± 129 m (P<0.05), and maximal walking distance from 245±124 to 349±155m (P<0.05). Once the efficacious dose of L-propionylcarnitine was assessed, its effect was compared to that of an equimolar dose of L-carnitine (500 mg i.v.) according to a double-blind, double-dummy, cross-over design. In 14 patients, both treatments improved walking capacity; however, the analysis of variance showed that the increase in maximal walking distance with L-propionylcarnitine was greater than that with L-carnitine (P < 0.05). Finally, in seven additional patients, the effects of L-propionylcarnitine and L-carnitine on the haemodynamics of the affected limb were assessed by an ultrasonic duplex system. Results indicated that both drugs did not affect the blood velocity and the blood flow rate in the ischaemic leg, thus suggesting that the beneficial effect on walking capacity was dependent on a metabolic effect. In conclusion, L-propionylcarnitine improves walking capacity in patients with peripheral vascular disease, probably acting through a metabolic mechanism. On a molar basis, this beneficial effect is greater than that observed with L-carnitine and, thus, the findings of the present study may have clinical relevance in terms of treatment cost and patient compliance.</description><subject>Arterial Occlusive Diseases - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Carnitine - administration & dosage</subject><subject>Carnitine - analogs & derivatives</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Exercise Test - drug effects</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Intermittent Claudication - drug therapy</subject><subject>Ischemia - drug therapy</subject><subject>L-carnitine</subject><subject>L-propionylcarnitine</subject><subject>Leg - blood supply</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>peripheral vascular disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><subject>walking capacity</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcGO0zAQhiMEWkrhEZB8QIhDU-w4thNOoBVQ0EocAGnFxZo4E-pu6mRtp7t9Lx4Ql1ZdcRrZ_-9vZvxn2RtGl4zW_O1w3w2-3QyTd9CHJU5-jeDjZglUUibEo2zGRFHktSzF42xGWS1yKavrp9mzEDaU0koyeZFdJKuQRTnL_nyfRvR28DbuydCRq3z0w2gHt-8NeGejdUh2Id0_HK0jdptsO-t-kzvobw7VwAjmAEnqCNGii4Hc2bgmB_64Rg892UEwUw-etDYgBHxHwBEwU8RFehc97NANU1iQdpiaHvOmt65dEOOHEPJhh56EOLX759mTLq2PL051nv389PHH5Sq_-vb5y-WHNCuvecwBu6aqqODYgZEMZEVBlaqpq06A4EYiKqWoMly2SrVly5FRYEXVtGCKsuHz7PWRm5a9nTBEvbXBYN-DwzSmVkUlBU-5zLP3R-O_ST12evR2C36vGdWH4PT_welzcPoUXEK8PPWami22D4BjUkl_ddLTH0LfeXDGhrNNMCWZOmDyo82GiPdnGfyNlooroVfXv3TJi6-S1oVe8b8M97_p</recordid><startdate>19920201</startdate><enddate>19920201</enddate><creator>BREVETTI, G.</creator><creator>PERNA, S.</creator><creator>SABBÀ, C.</creator><creator>ROSSINI, A.</creator><creator>SCOTTO DI UCCIO, V.</creator><creator>BERARDI, E.</creator><creator>GODI, L.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920201</creationdate><title>Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study</title><author>BREVETTI, G. ; PERNA, S. ; SABBÀ, C. ; ROSSINI, A. ; SCOTTO DI UCCIO, V. ; BERARDI, E. ; GODI, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-aefb88053efac61a680a747b98f5a53c6ee77707c36d77d4d3e10a128bdac24b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Arterial Occlusive Diseases - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Carnitine - administration & dosage</topic><topic>Carnitine - analogs & derivatives</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Exercise Test - drug effects</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Intermittent Claudication - drug therapy</topic><topic>Ischemia - drug therapy</topic><topic>L-carnitine</topic><topic>L-propionylcarnitine</topic><topic>Leg - blood supply</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>peripheral vascular disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><topic>walking capacity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BREVETTI, G.</creatorcontrib><creatorcontrib>PERNA, S.</creatorcontrib><creatorcontrib>SABBÀ, C.</creatorcontrib><creatorcontrib>ROSSINI, A.</creatorcontrib><creatorcontrib>SCOTTO DI UCCIO, V.</creatorcontrib><creatorcontrib>BERARDI, E.</creatorcontrib><creatorcontrib>GODI, L.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BREVETTI, G.</au><au>PERNA, S.</au><au>SABBÀ, C.</au><au>ROSSINI, A.</au><au>SCOTTO DI UCCIO, V.</au><au>BERARDI, E.</au><au>GODI, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>1992-02-01</date><risdate>1992</risdate><volume>13</volume><issue>2</issue><spage>251</spage><epage>255</epage><pages>251-255</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>The effects of L-propionylcarnitine on walking capacity were assessed in a group of patients with peripheral vascular disease. in 12 patients. 300mg of L-propnionylcarnitine, given intravenously as a single bolus did not affect walking capacity, while 600mg increased both initial claudication distance from the placebo value of 179±114 to 245 ± 129 m (P<0.05), and maximal walking distance from 245±124 to 349±155m (P<0.05). Once the efficacious dose of L-propionylcarnitine was assessed, its effect was compared to that of an equimolar dose of L-carnitine (500 mg i.v.) according to a double-blind, double-dummy, cross-over design. In 14 patients, both treatments improved walking capacity; however, the analysis of variance showed that the increase in maximal walking distance with L-propionylcarnitine was greater than that with L-carnitine (P < 0.05). Finally, in seven additional patients, the effects of L-propionylcarnitine and L-carnitine on the haemodynamics of the affected limb were assessed by an ultrasonic duplex system. Results indicated that both drugs did not affect the blood velocity and the blood flow rate in the ischaemic leg, thus suggesting that the beneficial effect on walking capacity was dependent on a metabolic effect. In conclusion, L-propionylcarnitine improves walking capacity in patients with peripheral vascular disease, probably acting through a metabolic mechanism. On a molar basis, this beneficial effect is greater than that observed with L-carnitine and, thus, the findings of the present study may have clinical relevance in terms of treatment cost and patient compliance.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>1555624</pmid><doi>10.1093/oxfordjournals.eurheartj.a060155</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 1992-02, Vol.13 (2), p.251-255 |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72865309 |
| source | MEDLINE; Oxford University Press Journals Digital Archive Legacy |
| subjects | Arterial Occlusive Diseases - drug therapy Biological and medical sciences Cardiovascular system Carnitine - administration & dosage Carnitine - analogs & derivatives Dose-Response Relationship, Drug Double-Blind Method Exercise Test - drug effects Hemodynamics - drug effects Humans Infusions, Intravenous Intermittent Claudication - drug therapy Ischemia - drug therapy L-carnitine L-propionylcarnitine Leg - blood supply Male Medical sciences Middle Aged peripheral vascular disease Pharmacology. Drug treatments Vasodilator agents. Cerebral vasodilators walking capacity |
| title | Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A07%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superiority%20of%20L-propionylcarnitine%20vs%20L-carnitine%20in%20improving%20walking%20capacity%20in%20patients%20with%20peripheral%20vascular%20disease:%20an%20acute,%20intravenous,%20double-blind,%20cross-over%20study&rft.jtitle=European%20heart%20journal&rft.au=BREVETTI,%20G.&rft.date=1992-02-01&rft.volume=13&rft.issue=2&rft.spage=251&rft.epage=255&rft.pages=251-255&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/oxfordjournals.eurheartj.a060155&rft_dat=%3Cproquest_cross%3E72865309%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72865309&rft_id=info:pmid/1555624&rfr_iscdi=true |